XiaoMi-AI文件搜索系统
World File Search Systemclinically
建议所有乳腺癌患者进行 HER2 检测以指导治疗。1 罗氏 HER2 (4B5) 检测*是唯一经过临床验证的
1 Wolff AC 等。乳腺癌中人表皮生长因子受体 2 检测：ASCO–美国病理学家学院指南更新。https://ascopubs. org/doi/full/10.1200/JCO.22.02864；访问日期：2023年11月1日。2 数据摘自 NordiQC 运行报告 (https://www.nordiqc.org)；访问日期：2023年11月1日。指 VENTANA 抗 HER2/neu (4B5) 兔单克隆抗体和 PATHWAY 抗 HER2/neu (4B5) 兔单克隆抗体。
推荐引用推荐引用Sulaiman A，McGarry S，Chilumula SC，Kandunuri R，Vinod V.抑制临床翻译的方法
摘要：三阴性乳腺癌（TNBC）是乳腺癌的亚型，由于缺乏有效治疗的特定靶标，由于缺乏乳腺癌相关的大多数死亡而过分地说明了大多数与乳腺癌相关的死亡。在这篇综述中，我们强调了转化生长因子β家族（TGF-β）途径的复杂性，并讨论TGF-β途径的失调如何促进TNBC中的致癌属性，从而对患者预后产生负面影响。此外，我们讨论了最近的发现，该发现突出了TGF-β抑制作用，作为一种有效的方法，是针对间质（CD44 + /CD24-）和上皮（ALDH高）癌细胞（CSC）种群的有效方法。CSC与肿瘤发生，转移，复发，抗性和患者预后减少有关。但是，由于差异信号途径富集和可塑性，这些人群仍然很难靶向并坚持不懈地作为一个主要的障碍，禁止成功治疗。这篇评论强调了TGF-β作为化学耐药性，放射性和患者预后降低的驱动力的重要性，并突出了新型治疗策略，这些治疗策略可调节TGF-β，促进癌症的进展并降低通过靶向TNBC中CSC群体的抗药性产生速度，从而降低TNBC的毒素。基于临床试验的靶向靶向的潜在TGF-β抑制剂进行了进一步研究，这可能导致开发新的疗法以改善TNBC患者预后。
社区心理健康团队运营政策
6.13.2请注意，主动审查过程是一个适当的系统，可以在等待治疗开始时确保患者的安全。 If, following an assessment, a patient needs immediate allocation for care co-ordination and there is no capacity amongst staff to be allocated as the patient's care coordinator at that time, the team managers will be required to undertake a caseload review and re-allocate a non CPA patient from a clinician's caseload onto the Active Review caseload, where clinically safe to do so, thus creating capacity for immediate care co- ordination for the patient to那个特殊的临床医生。 内部过渡6.13.2请注意，主动审查过程是一个适当的系统，可以在等待治疗开始时确保患者的安全。If, following an assessment, a patient needs immediate allocation for care co-ordination and there is no capacity amongst staff to be allocated as the patient's care coordinator at that time, the team managers will be required to undertake a caseload review and re-allocate a non CPA patient from a clinician's caseload onto the Active Review caseload, where clinically safe to do so, thus creating capacity for immediate care co- ordination for the patient to那个特殊的临床医生。内部过渡
心力衰竭教学计划-GPSA
• Heart failure is more common in Aboriginal and Torres Strait Islander people • HFrEF and HFpEF are often clinically indistinguishable • Echocardiography is the single most useful investigation in patients with suspected HF, but can be difficult to interpret • BNP level is helpful where diagnosis is unclear, especially as a rule-out test • All patients should have aggressive management of risk factors and comorbidities, particularly hypertension • ACE HFREF患者的抑制剂（或ARB），β受体阻滞剂和矿物皮质激素受体拮抗剂（MRA）改善了HFREF患者的存活和减少的住院治疗。是所有患者的重要策略
Zolbetuximab注射（Vyloy）
来自2个随机，双遮盖的，安慰剂对照的III期试验（Spotlight and Glow）的证据表明，Zolbetuximab添加到氟吡啶丁胺 - 和铂的化学疗法中时（改良的氟尿嘧啶加氟尿嘧啶加上白细胞素的改性，以及对OXALIPPATIN 6 [MFOLFOLFOFFOOX 6]或CAPECITIPLAT []或CAPECITIPLAT []或CAPECITIPLATIN []或CAPECALIPLATIN []患有局部晚期不可切除或转移性HER2-阴性胃癌或GEJ腺癌的患者具有CLDN18.2阳性的肿瘤患者，从而增加了临床益处。The SPOTLIGHT trial (N = 565) demonstrated that treatment with zolbetuximab in combination with mFOLFOX6 resulted in statistically significant and clinically meaningful improvements in overall survival (OS) (hazard ratio [HR] = 0.784; 95% confidence interval [CI], 0.644 to 0.954; P = 0.0075) and progression-free survival (PFS) (HR = 0.751;与安慰剂结合使用MFOLFOX6，CI，0.598至0.942；The GLOW trial (N = 507) similarly demonstrated that treatment with zolbetuximab in combination with CAPOX resulted in statistically significant and clinically important meaningful improvements in OS (HR = 0.763; 95% CI, 0.622 to 0.936; P = 0.0047) and PFS (HR = 0.687; 95% CI, 0.544 to 0.866; P = 0.0007),与安慰剂与Capox结合使用相比。在关键试验中，与单独的化学疗法相比，用化学疗法结合使用Zolbetuximab与化学疗法结合使用，与恶心，呕吐和输注相关的反应的风险增加有关。但是，PERC与临床专家一致，这些不良事件（AES）在临床实践中可能是可以管理的。
UNSW FMH AI能力声明儿童癌症研究所v0.1
o Encode and democratize knowledge accumulated by curating >1000 patients o Integrate patient's tumour molecular profile with treatment and high-throughput drug response data o Expand access to data accumulated to all researchers o Identify novel cancer drivers for functional genomic testing • Develop a paediatric pan-cancer classification and prognostic tool utilising machine learning methods to support clinicians in accurate diagnosis and treatment recommendations in a clinically relevant timeframe • Develop自然语言界面使用大型语言模型来改善可访问性和简化变体策划
Cadth报销建议
Evidence from one open-label phase III randomized controlled trial involving a total of 886 patients with locally advanced or metastatic urothelial cancer (Study EV-302) showed that treatment with enfortumab vedotin in combination with pembrolizumab demonstrated a clinically meaningful benefit compared to platinum plus gemcitabine chemotherapy (PLAT + GEM) in improving overall survival (HR: 0.468 [95% CI: 0.376，0.582]; p <0.00001），无进展生存率（HR = 0.450，95％CI：0.377，0.538; p <0.00001）和客观响应率（差异= 23.3％[95％CI，16.8％至29.6％]；Enfortumab Vedotin与Pembrolizumab结合使用的安全性与Enfortumab Vedotin单一疗法和pembrolizumab单一疗法的已知安全概况一致。
猫哮喘的临床，诊断和治疗方面
抽象的猫哮喘由一种炎症性疾病组成，其尾部呼吸道的状况是猫的状况，该物种是唯一具有与人类类似综合征的综合症的物种。您的病理生理学尚未完全了解，但众所周知，暴露于空气过敏原的反应加剧。受影响的动物通常是年轻的和中年，对种族和性别没有偏见，尽管研究表明暹罗氏症存在更大的倾向。clinically can manifest itself by cough, dyspnea, sneezing, exercise intolerance, tachypnea, expiratory sibilos and/or noisy breathing, being challenging diagnosis, including historical, clinical signs, found in physical examination and association with diagnostic tests, such as bronchoscopy, microbiological and cytological analysis of the Broncholar Lavalar, exams, exams Image, pulmonary function测试和实验室测试。 治疗基于支气管扩张剂，皮质类固醇和环境管理的给药，旨在减少对过敏原的暴露。 本研究的目的是进行有关猫哮喘的文献综述，以解决该疾病的临床，诊断和治疗方面。 基于PubMed，Scielo和Google学术平台的基础研究的文献叙事评论，以及使用兽医学教科书。 关键字：猫哮喘；过度反应性；呼吸道。 抽象的猫阿斯特玛是一种属于猫的尾部呼吸道的无视，该物种是唯一呈现一种类似于人类的综合征的物种。clinically can manifest itself by cough, dyspnea, sneezing, exercise intolerance, tachypnea, expiratory sibilos and/or noisy breathing, being challenging diagnosis, including historical, clinical signs, found in physical examination and association with diagnostic tests, such as bronchoscopy, microbiological and cytological analysis of the Broncholar Lavalar, exams, exams Image, pulmonary function测试和实验室测试。治疗基于支气管扩张剂，皮质类固醇和环境管理的给药，旨在减少对过敏原的暴露。本研究的目的是进行有关猫哮喘的文献综述，以解决该疾病的临床，诊断和治疗方面。基于PubMed，Scielo和Google学术平台的基础研究的文献叙事评论，以及使用兽医学教科书。关键字：猫哮喘；过度反应性；呼吸道。抽象的猫阿斯特玛是一种属于猫的尾部呼吸道的无视，该物种是唯一呈现一种类似于人类的综合征的物种。其病理生理学尚未完全了解，但众所周知，会发生对暴露于空气过敏原的反应加剧。受影响的动物倾向于年轻和中年，而对品种或性别没有偏爱，尽管研究表明，暹罗人的倾向更大。Clinically, it can manifest itself as coughing, dyspnea, sneezing, exercise intolerance, tachypnea, expiratory wheezing and/or noisy breathing, making its diagnosis challenging, including history, clinical signs, physical examination findings and association with diagnostic tests, such as bronchoscopy, microbiological and cytological analysis of bronchoalveolar lavage, imaging tests,肺功能测试和实验室测试。治疗基于支气管扩张剂，皮质类固醇和环境管理的给药，旨在减少对过敏原的暴露。
人力资源政策
Individuals seeking an exemption for medical reasons must submit a completed COVID-19 Vaccination Medical Exemption Request Form to Employee Health (VaxMedEx@mhs.net) and must provide a Medical Certification Form completed, signed and dated by their licensed healthcare provider, which must (1) contain all information specifying which of the authorized COVID-19 vaccines are clinically contraindicated; （2）概述了员工对疫苗的特定公认的临床禁忌症或CDC征求的延迟接种疫苗的原因； （3）包含认证提供者的声明，建议根据公认的临床禁忌症豁免个人的疫苗要求，或者根据CDC建议延迟了疫苗接种。认证医疗保健提供者可能不是要求豁免的个人，并且必须在其各自的实践范围内行事。
新闻稿，2025年1月21日，韩国授予Diamyd Medical的Precision Medicine in Autommune Diabetes
1st-line benefit in combination with widely approved CDK4/6 inhibitors Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful无进展生存期（PFS）的主要终点的改善。该试验评估了切换到芳香酶抑制剂（AI）（ANASTROZOLE或LETROOZOLE）与CDK4/6抑制剂在一线治疗激素受体（HR）患者（HR）蛋白（HR） - 蛋白蛋白酶（Her2）型乳腺较大较大的癌症中的一线治疗中，与CDK4/6抑制剂结合使用了CDK4/6抑制剂，将切换到持续的护理标准治疗。